1 / 11

Featured Article :

Featured Article :. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes.

henry-pittman
Télécharger la présentation

Featured Article :

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes Julio Rosenstock, Ante Jelaska, Guillaume Frappin, Afshin Salsali, Gabriel Kim, Hans J. Woerle, and Uli C. Broedl, on behalf of the EMPA-REG MDI Trial Investigators Diabetes Care Volume 37: 1815-1823 July, 2014

  2. STUDY OBJECTIVE • To investigate the efficacy and safety of empagliflozin, added to multiple daily injections (MDI) of insulin in obese patients with type 2 diabetes mellitus (T2DM) Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  3. STUDY DESIGN AND METHODS • Patients inadequately controlled on MDI insulin ± metformin were randomized and treated with once-daily empagliflozin 10 mg, empagliflozin 25 mg, or placebo for 52 weeks • Insulin dose was to remain stable in weeks 1–18, was adjusted to meet glucose targets in weeks 19–40, and then remain stable in weeks 41–52 • Primary end point was change from baseline in HbA1c at week 18 • Secondary end points were changes from baseline in insulin dose, weight, and HbA1c at week 52 Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  4. RESULTS • Changes from baseline in HbA1c were –0.50 ± 0.05% for placebo versus –0.94 ± 0.05% and –1.02 ± 0.05% for empagliflozin 10 mg and empagliflozin 25 mg, respectively, at week 18 • At week 52, further reductions with insulin titration resulted in changes from baseline in HbA1c of –0.81 ± 0.08, –1.18 ± 0.08, and –1.27 ± 0.08% with placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively, and final HbA1c of 7.5, 7.2, and 7.1%, respectively Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  5. RESULTS • More patients attained HbA1c <7% with empagliflozin versus placebo • Empagliflozin 10 mg and empagliflozin 25 mg reduced insulin doses and weight versus placebo at week 52 Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  6. Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  7. Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  8. Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  9. Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  10. Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

  11. CONCLUSIONS • In obese, difficult-to-treat patients with T2DM inadequately controlled on high MDI insulin doses, empagliflozin improved glycemic control and reduced weight without increasing hypoglycemia risk and with lower insulin requirements Rosenstock J. et al. Diabetes Care 2014;37:1815-1823

More Related